Economic analysis of a phase III study of G-CSF vs placebo following allogeneic blood stem cell transplantation

Bone Marrow Transplantation

Volumn 26, Issue 6, 2000, Pages 663-666

  Stinson, T J ^a   Adams, J R ^a   Bishop, M R ^b,c   Kruse, S ^b   Tarantolo, S ^b   Bennett, C L ^a,d,e  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e JESSE BROWN VA MEDICAL CENTER   (United States)

Author keywords

Allogeneic; Cost effectiveness; Costs; Granulocyte colony stimulating factor; Peripheral blood stem cell transplant

Indexed keywords

ANTIBIOTIC AGENT; CYCLOSPORIN A; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; PLACEBO;

ACUTE DISEASE; ADOLESCENT; ADULT; ALLOTRANSPLANTATION; ANTIBIOTIC THERAPY; ARTICLE; BLOOD TRANSFUSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG COST; ECONOMIC EVALUATION; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITAL COST; HOSPITALIZATION; HUMAN; LABORATORY; MALE; NEUTROPENIA; NEUTROPHIL; OUTPATIENT; PHASE 3 CLINICAL TRIAL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RADIOLOGY; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY CARE; SURVIVAL; THROMBOCYTE COUNT;

EID: 0033804299     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702579     Document Type: Article

References (23)

1. Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by GM-CSF or G-CSF: Potential role in allogeneic marrow transplantation
2. Allogeneic blood stem cell collection following mobilization with low dose granulocyte colony stimulating factor
3. Allogeneic blood stem cell transplants for heamatological malignancy: Preliminary comparison of outcomes with bone marrow transplantation
4. Allogeneic blood cell transplantation without post transplant colony-stimulating factors in patients with hematopoietic neoplasm
5. Hematopoietic recovery after allogeneic blood stem cell transplantation compared with bone marrow transplantation in patients with hematologic malignancies
6. Peripheral blood stem cells for allografting
7. Granulocyte colony stimulating factor accelerates neutrophil engraftment following peripheral blood stem cell transplantation: A prospective randomized trial
8. Low dose filgrastim significantly enhances neutrophil recovery following autologous peripheral blood stem cell transplantation in patients with lymphoproliferative disorders: Evidence for clinical and economic benefit
9. G-CSF after peripheral blood stem cell transplantation in lymphoma patients significantly accelerated neutrophil recovery and shortened time in hospital
10. Granulocyte-colony stimulating factor after allogeneic transplantation
11. Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate containing graft versus host disease prophylaxis
12. Phase I/II trial of recombinant GM-CSF following allogeneic bone marrow transplantation
13. Cost analysis of a randomized trial comparing G-CSF to standard supportive care following PBSC transplantation
14. A randomized, double-blind trial of filgrastim versus placebo following allogeneic blood stem cell transplantation
15. Valuing clinical strategies early in development: A cost analysis of allogeneic peripheral blood stem cell transplantation
16. Costs of care for high-dose therapy and autologous transplantation for non-Hodgkin's lymphoma: Results from the University of Nebraska Medical Center 1989 through 1995
17. Costs of care and outcomes for high dose therapy and autologous transplantation for lymphoid malignancies: Results from the University of Nebraska 1987-1991
18. Granulocyte macrophage colony stimulating factor as adjunct therapy in relapsed lymphoid malignancy: Implications for economic analyses of phase III clinical trials
19. A cost-analysis of filgrastim for the prevention of neutropenia in pediatric T-cell leukemia and advanced lymphoma: A case for prospective economic analysis in cooperative group trials
20. Economic analysis of a randomized placebo-controlled phase III study of granulocyte macrophage colony stimulating factor in adult patients with acute myelogenous leukemia
21. Human granulocyte colony stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia
22. Longterm follow-up of high-risk allogeneic peripheral blood stem cell transplant recipients: Graft versus host disease and transplant-related mortality
23. A prospective randomized trial of peripheral blood stem cells or marrow for patients undergoing allogeneic transplantation for hematologic malignancies